Global Decitabine Drug Market

Decitabine Drug Comprehensive Study by Type (Prescription, Over-the-Counter), Application (Myelodysplastic syndrome, Acute Myeloid Leukemia), Distribution Channel (Hospital Pharmacies, Drug Store, Retail Pharmacies, Online, Others), End-user (Hospitals, Clinics, Others) Players and Region - Global Market Outlook to 2028

Decitabine Drug Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Decitabine Drug Market?

It is estimated that more than 10,000 new cases of myelodysplastic syndrome(MDS) occur in the United States annually. Decitabine is an anti-cancer chemotherapy drug used for the treatment of myelodysplastic syndrome (certain types of blood or bone marrow cancer). It is a class of medications called hypomethylation agents that helps the bone marrow to produce normal blood cells and by killing abnormal cells in the bone marrow. The factors such as Increased Prevalence of Myelodysplastic Syndrome among People, Development of New Diagnostic Centres and Hospitals and Increase in Healthcare Expenditure in Developing Regions such as India and China are driving the global decitabine drug market.

Highlights from Decitabine Drug Market Study
AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledScinoPharm (Taiwan), Otsuka Pharmaceutical Co., Ltd. (Japan), Sandoz (Germany), Dr. Reddy's Laboratories (India), Midas Pharma GmbH (Germany), LGM Pharma (United States), Astex Therapeutics (United States), Accord Healthcare Ltd. (United Kingdom), Sun Pharmaceutical Industries Ltd. (India) and Cipla (India)


The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that Indian Players will contribute to the maximum growth of Global Decitabine Drug market throughout the forecasted period.

ScinoPharm (Taiwan), Otsuka Pharmaceutical Co., Ltd. (Japan), Sandoz (Germany), Dr. Reddy's Laboratories (India), Midas Pharma GmbH (Germany), LGM Pharma (United States), Astex Therapeutics (United States), Accord Healthcare Ltd. (United Kingdom), Sun Pharmaceutical Industries Ltd. (India) and Cipla (India) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Beijing Lunarsun Pharmaceutical Co., Ltd. (China), Lupin (India), Taj Pharmaceuticals Limited (India) and Innopharma, Inc. (United States).

Decitabine Drug Market Segmentation:
ScopeSub-Segments
Application / End UserMyelodysplastic syndrome and Acute Myeloid Leukemia
TypePrescription and Over-the-Counter
Distribution ChannelHospital Pharmacies,Drug Store,Retail Pharmacies,Online,Others
End-userHospitals,Clinics,Others


On the basis of geography, the market of Decitabine Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Government Funding for the Cancer Research and Adoption of Novel Technologies By Manufacturers

Market Growth Drivers:
Increased Prevalence of Myelodysplastic Syndrome among People, Development of New Diagnostic Centres and Hospitals and Increase in Healthcare Expenditure in Developing Regions such as India and China

Challenges:
Stringent Government Rules and Regulations

Restraints:
Side Effects of the Decitabine Drug

Opportunities:
Huge Investments by Major Players, Increased Research and Development Investment and Growth in the Healthcare Industry

Key Target Audience
Decitabine Drug Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies, Research Professionals and End-users

Market Leaders & Development Strategies
In June 2020, Dr. Reddy's Laboratories Ltd. has announced that it has completed the acquisition of select divisions of Wockhardt Limited’s branded generics business in India and a few other international territories of Nepal, Sri Lanka, Bhutan and Maldives.



Report Objectives / Segmentation Covered

By Type
  • Prescription
  • Over-the-Counter
By Application
  • Myelodysplastic syndrome
  • Acute Myeloid Leukemia
By Distribution Channel
  • Hospital Pharmacies
  • Drug Store
  • Retail Pharmacies
  • Online
  • Others

By End-user
  • Hospitals
  • Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Myelodysplastic Syndrome among People
      • 3.2.2. Development of New Diagnostic Centres and Hospitals
      • 3.2.3. Increase in Healthcare Expenditure in Developing Regions such as India and China
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Increasing Government Funding for the Cancer Research
      • 3.4.2. Adoption of Novel Technologies By Manufacturers
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Decitabine Drug, by Type, Application, Distribution Channel, End-user and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Decitabine Drug (Value)
      • 5.2.1. Global Decitabine Drug by: Type (Value)
        • 5.2.1.1. Prescription
        • 5.2.1.2. Over-the-Counter
      • 5.2.2. Global Decitabine Drug by: Application (Value)
        • 5.2.2.1. Myelodysplastic syndrome
        • 5.2.2.2. Acute Myeloid Leukemia
      • 5.2.3. Global Decitabine Drug by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Drug Store
        • 5.2.3.3. Retail Pharmacies
        • 5.2.3.4. Online
        • 5.2.3.5. Others
      • 5.2.4. Global Decitabine Drug by: End-user (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Clinics
        • 5.2.4.3. Others
      • 5.2.5. Global Decitabine Drug Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Decitabine Drug (Volume)
      • 5.3.1. Global Decitabine Drug by: Type (Volume)
        • 5.3.1.1. Prescription
        • 5.3.1.2. Over-the-Counter
      • 5.3.2. Global Decitabine Drug by: Application (Volume)
        • 5.3.2.1. Myelodysplastic syndrome
        • 5.3.2.2. Acute Myeloid Leukemia
      • 5.3.3. Global Decitabine Drug by: Distribution Channel (Volume)
        • 5.3.3.1. Hospital Pharmacies
        • 5.3.3.2. Drug Store
        • 5.3.3.3. Retail Pharmacies
        • 5.3.3.4. Online
        • 5.3.3.5. Others
      • 5.3.4. Global Decitabine Drug by: End-user (Volume)
        • 5.3.4.1. Hospitals
        • 5.3.4.2. Clinics
        • 5.3.4.3. Others
      • 5.3.5. Global Decitabine Drug Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Decitabine Drug (Price)
      • 5.4.1. Global Decitabine Drug by: Type (Price)
  • 6. Decitabine Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. ScinoPharm (Taiwan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Otsuka Pharmaceutical Co., Ltd. (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sandoz (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Dr. Reddy's Laboratories (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Midas Pharma GmbH (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. LGM Pharma (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Astex Therapeutics (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Accord Healthcare Ltd. (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sun Pharmaceutical Industries Ltd. (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Cipla (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Decitabine Drug Sale, by Type, Application, Distribution Channel, End-user and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Decitabine Drug (Value)
      • 7.2.1. Global Decitabine Drug by: Type (Value)
        • 7.2.1.1. Prescription
        • 7.2.1.2. Over-the-Counter
      • 7.2.2. Global Decitabine Drug by: Application (Value)
        • 7.2.2.1. Myelodysplastic syndrome
        • 7.2.2.2. Acute Myeloid Leukemia
      • 7.2.3. Global Decitabine Drug by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Drug Store
        • 7.2.3.3. Retail Pharmacies
        • 7.2.3.4. Online
        • 7.2.3.5. Others
      • 7.2.4. Global Decitabine Drug by: End-user (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Clinics
        • 7.2.4.3. Others
      • 7.2.5. Global Decitabine Drug Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Decitabine Drug (Volume)
      • 7.3.1. Global Decitabine Drug by: Type (Volume)
        • 7.3.1.1. Prescription
        • 7.3.1.2. Over-the-Counter
      • 7.3.2. Global Decitabine Drug by: Application (Volume)
        • 7.3.2.1. Myelodysplastic syndrome
        • 7.3.2.2. Acute Myeloid Leukemia
      • 7.3.3. Global Decitabine Drug by: Distribution Channel (Volume)
        • 7.3.3.1. Hospital Pharmacies
        • 7.3.3.2. Drug Store
        • 7.3.3.3. Retail Pharmacies
        • 7.3.3.4. Online
        • 7.3.3.5. Others
      • 7.3.4. Global Decitabine Drug by: End-user (Volume)
        • 7.3.4.1. Hospitals
        • 7.3.4.2. Clinics
        • 7.3.4.3. Others
      • 7.3.5. Global Decitabine Drug Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Decitabine Drug (Price)
      • 7.4.1. Global Decitabine Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Decitabine Drug: by Type(USD Million)
  • Table 2. Decitabine Drug Prescription , by Region USD Million (2017-2022)
  • Table 3. Decitabine Drug Over-the-Counter , by Region USD Million (2017-2022)
  • Table 4. Decitabine Drug: by Application(USD Million)
  • Table 5. Decitabine Drug Myelodysplastic syndrome , by Region USD Million (2017-2022)
  • Table 6. Decitabine Drug Acute Myeloid Leukemia , by Region USD Million (2017-2022)
  • Table 7. Decitabine Drug: by Distribution Channel(USD Million)
  • Table 8. Decitabine Drug Hospital Pharmacies , by Region USD Million (2017-2022)
  • Table 9. Decitabine Drug Drug Store , by Region USD Million (2017-2022)
  • Table 10. Decitabine Drug Retail Pharmacies , by Region USD Million (2017-2022)
  • Table 11. Decitabine Drug Online , by Region USD Million (2017-2022)
  • Table 12. Decitabine Drug Others , by Region USD Million (2017-2022)
  • Table 13. Decitabine Drug: by End-user(USD Million)
  • Table 14. Decitabine Drug Hospitals , by Region USD Million (2017-2022)
  • Table 15. Decitabine Drug Clinics , by Region USD Million (2017-2022)
  • Table 16. Decitabine Drug Others , by Region USD Million (2017-2022)
  • Table 17. South America Decitabine Drug, by Country USD Million (2017-2022)
  • Table 18. South America Decitabine Drug, by Type USD Million (2017-2022)
  • Table 19. South America Decitabine Drug, by Application USD Million (2017-2022)
  • Table 20. South America Decitabine Drug, by Distribution Channel USD Million (2017-2022)
  • Table 21. South America Decitabine Drug, by End-user USD Million (2017-2022)
  • Table 22. Brazil Decitabine Drug, by Type USD Million (2017-2022)
  • Table 23. Brazil Decitabine Drug, by Application USD Million (2017-2022)
  • Table 24. Brazil Decitabine Drug, by Distribution Channel USD Million (2017-2022)
  • Table 25. Brazil Decitabine Drug, by End-user USD Million (2017-2022)
  • Table 26. Argentina Decitabine Drug, by Type USD Million (2017-2022)
  • Table 27. Argentina Decitabine Drug, by Application USD Million (2017-2022)
  • Table 28. Argentina Decitabine Drug, by Distribution Channel USD Million (2017-2022)
  • Table 29. Argentina Decitabine Drug, by End-user USD Million (2017-2022)
  • Table 30. Rest of South America Decitabine Drug, by Type USD Million (2017-2022)
  • Table 31. Rest of South America Decitabine Drug, by Application USD Million (2017-2022)
  • Table 32. Rest of South America Decitabine Drug, by Distribution Channel USD Million (2017-2022)
  • Table 33. Rest of South America Decitabine Drug, by End-user USD Million (2017-2022)
  • Table 34. Asia Pacific Decitabine Drug, by Country USD Million (2017-2022)
  • Table 35. Asia Pacific Decitabine Drug, by Type USD Million (2017-2022)
  • Table 36. Asia Pacific Decitabine Drug, by Application USD Million (2017-2022)
  • Table 37. Asia Pacific Decitabine Drug, by Distribution Channel USD Million (2017-2022)
  • Table 38. Asia Pacific Decitabine Drug, by End-user USD Million (2017-2022)
  • Table 39. China Decitabine Drug, by Type USD Million (2017-2022)
  • Table 40. China Decitabine Drug, by Application USD Million (2017-2022)
  • Table 41. China Decitabine Drug, by Distribution Channel USD Million (2017-2022)
  • Table 42. China Decitabine Drug, by End-user USD Million (2017-2022)
  • Table 43. Japan Decitabine Drug, by Type USD Million (2017-2022)
  • Table 44. Japan Decitabine Drug, by Application USD Million (2017-2022)
  • Table 45. Japan Decitabine Drug, by Distribution Channel USD Million (2017-2022)
  • Table 46. Japan Decitabine Drug, by End-user USD Million (2017-2022)
  • Table 47. India Decitabine Drug, by Type USD Million (2017-2022)
  • Table 48. India Decitabine Drug, by Application USD Million (2017-2022)
  • Table 49. India Decitabine Drug, by Distribution Channel USD Million (2017-2022)
  • Table 50. India Decitabine Drug, by End-user USD Million (2017-2022)
  • Table 51. South Korea Decitabine Drug, by Type USD Million (2017-2022)
  • Table 52. South Korea Decitabine Drug, by Application USD Million (2017-2022)
  • Table 53. South Korea Decitabine Drug, by Distribution Channel USD Million (2017-2022)
  • Table 54. South Korea Decitabine Drug, by End-user USD Million (2017-2022)
  • Table 55. Taiwan Decitabine Drug, by Type USD Million (2017-2022)
  • Table 56. Taiwan Decitabine Drug, by Application USD Million (2017-2022)
  • Table 57. Taiwan Decitabine Drug, by Distribution Channel USD Million (2017-2022)
  • Table 58. Taiwan Decitabine Drug, by End-user USD Million (2017-2022)
  • Table 59. Australia Decitabine Drug, by Type USD Million (2017-2022)
  • Table 60. Australia Decitabine Drug, by Application USD Million (2017-2022)
  • Table 61. Australia Decitabine Drug, by Distribution Channel USD Million (2017-2022)
  • Table 62. Australia Decitabine Drug, by End-user USD Million (2017-2022)
  • Table 63. Rest of Asia-Pacific Decitabine Drug, by Type USD Million (2017-2022)
  • Table 64. Rest of Asia-Pacific Decitabine Drug, by Application USD Million (2017-2022)
  • Table 65. Rest of Asia-Pacific Decitabine Drug, by Distribution Channel USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific Decitabine Drug, by End-user USD Million (2017-2022)
  • Table 67. Europe Decitabine Drug, by Country USD Million (2017-2022)
  • Table 68. Europe Decitabine Drug, by Type USD Million (2017-2022)
  • Table 69. Europe Decitabine Drug, by Application USD Million (2017-2022)
  • Table 70. Europe Decitabine Drug, by Distribution Channel USD Million (2017-2022)
  • Table 71. Europe Decitabine Drug, by End-user USD Million (2017-2022)
  • Table 72. Germany Decitabine Drug, by Type USD Million (2017-2022)
  • Table 73. Germany Decitabine Drug, by Application USD Million (2017-2022)
  • Table 74. Germany Decitabine Drug, by Distribution Channel USD Million (2017-2022)
  • Table 75. Germany Decitabine Drug, by End-user USD Million (2017-2022)
  • Table 76. France Decitabine Drug, by Type USD Million (2017-2022)
  • Table 77. France Decitabine Drug, by Application USD Million (2017-2022)
  • Table 78. France Decitabine Drug, by Distribution Channel USD Million (2017-2022)
  • Table 79. France Decitabine Drug, by End-user USD Million (2017-2022)
  • Table 80. Italy Decitabine Drug, by Type USD Million (2017-2022)
  • Table 81. Italy Decitabine Drug, by Application USD Million (2017-2022)
  • Table 82. Italy Decitabine Drug, by Distribution Channel USD Million (2017-2022)
  • Table 83. Italy Decitabine Drug, by End-user USD Million (2017-2022)
  • Table 84. United Kingdom Decitabine Drug, by Type USD Million (2017-2022)
  • Table 85. United Kingdom Decitabine Drug, by Application USD Million (2017-2022)
  • Table 86. United Kingdom Decitabine Drug, by Distribution Channel USD Million (2017-2022)
  • Table 87. United Kingdom Decitabine Drug, by End-user USD Million (2017-2022)
  • Table 88. Netherlands Decitabine Drug, by Type USD Million (2017-2022)
  • Table 89. Netherlands Decitabine Drug, by Application USD Million (2017-2022)
  • Table 90. Netherlands Decitabine Drug, by Distribution Channel USD Million (2017-2022)
  • Table 91. Netherlands Decitabine Drug, by End-user USD Million (2017-2022)
  • Table 92. Rest of Europe Decitabine Drug, by Type USD Million (2017-2022)
  • Table 93. Rest of Europe Decitabine Drug, by Application USD Million (2017-2022)
  • Table 94. Rest of Europe Decitabine Drug, by Distribution Channel USD Million (2017-2022)
  • Table 95. Rest of Europe Decitabine Drug, by End-user USD Million (2017-2022)
  • Table 96. MEA Decitabine Drug, by Country USD Million (2017-2022)
  • Table 97. MEA Decitabine Drug, by Type USD Million (2017-2022)
  • Table 98. MEA Decitabine Drug, by Application USD Million (2017-2022)
  • Table 99. MEA Decitabine Drug, by Distribution Channel USD Million (2017-2022)
  • Table 100. MEA Decitabine Drug, by End-user USD Million (2017-2022)
  • Table 101. Middle East Decitabine Drug, by Type USD Million (2017-2022)
  • Table 102. Middle East Decitabine Drug, by Application USD Million (2017-2022)
  • Table 103. Middle East Decitabine Drug, by Distribution Channel USD Million (2017-2022)
  • Table 104. Middle East Decitabine Drug, by End-user USD Million (2017-2022)
  • Table 105. Africa Decitabine Drug, by Type USD Million (2017-2022)
  • Table 106. Africa Decitabine Drug, by Application USD Million (2017-2022)
  • Table 107. Africa Decitabine Drug, by Distribution Channel USD Million (2017-2022)
  • Table 108. Africa Decitabine Drug, by End-user USD Million (2017-2022)
  • Table 109. North America Decitabine Drug, by Country USD Million (2017-2022)
  • Table 110. North America Decitabine Drug, by Type USD Million (2017-2022)
  • Table 111. North America Decitabine Drug, by Application USD Million (2017-2022)
  • Table 112. North America Decitabine Drug, by Distribution Channel USD Million (2017-2022)
  • Table 113. North America Decitabine Drug, by End-user USD Million (2017-2022)
  • Table 114. United States Decitabine Drug, by Type USD Million (2017-2022)
  • Table 115. United States Decitabine Drug, by Application USD Million (2017-2022)
  • Table 116. United States Decitabine Drug, by Distribution Channel USD Million (2017-2022)
  • Table 117. United States Decitabine Drug, by End-user USD Million (2017-2022)
  • Table 118. Canada Decitabine Drug, by Type USD Million (2017-2022)
  • Table 119. Canada Decitabine Drug, by Application USD Million (2017-2022)
  • Table 120. Canada Decitabine Drug, by Distribution Channel USD Million (2017-2022)
  • Table 121. Canada Decitabine Drug, by End-user USD Million (2017-2022)
  • Table 122. Mexico Decitabine Drug, by Type USD Million (2017-2022)
  • Table 123. Mexico Decitabine Drug, by Application USD Million (2017-2022)
  • Table 124. Mexico Decitabine Drug, by Distribution Channel USD Million (2017-2022)
  • Table 125. Mexico Decitabine Drug, by End-user USD Million (2017-2022)
  • Table 126. Decitabine Drug Sales: by Type(K Tons)
  • Table 127. Decitabine Drug Sales Prescription , by Region K Tons (2017-2022)
  • Table 128. Decitabine Drug Sales Over-the-Counter , by Region K Tons (2017-2022)
  • Table 129. Decitabine Drug Sales: by Application(K Tons)
  • Table 130. Decitabine Drug Sales Myelodysplastic syndrome , by Region K Tons (2017-2022)
  • Table 131. Decitabine Drug Sales Acute Myeloid Leukemia , by Region K Tons (2017-2022)
  • Table 132. Decitabine Drug Sales: by Distribution Channel(K Tons)
  • Table 133. Decitabine Drug Sales Hospital Pharmacies , by Region K Tons (2017-2022)
  • Table 134. Decitabine Drug Sales Drug Store , by Region K Tons (2017-2022)
  • Table 135. Decitabine Drug Sales Retail Pharmacies , by Region K Tons (2017-2022)
  • Table 136. Decitabine Drug Sales Online , by Region K Tons (2017-2022)
  • Table 137. Decitabine Drug Sales Others , by Region K Tons (2017-2022)
  • Table 138. Decitabine Drug Sales: by End-user(K Tons)
  • Table 139. Decitabine Drug Sales Hospitals , by Region K Tons (2017-2022)
  • Table 140. Decitabine Drug Sales Clinics , by Region K Tons (2017-2022)
  • Table 141. Decitabine Drug Sales Others , by Region K Tons (2017-2022)
  • Table 142. South America Decitabine Drug Sales, by Country K Tons (2017-2022)
  • Table 143. South America Decitabine Drug Sales, by Type K Tons (2017-2022)
  • Table 144. South America Decitabine Drug Sales, by Application K Tons (2017-2022)
  • Table 145. South America Decitabine Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 146. South America Decitabine Drug Sales, by End-user K Tons (2017-2022)
  • Table 147. Brazil Decitabine Drug Sales, by Type K Tons (2017-2022)
  • Table 148. Brazil Decitabine Drug Sales, by Application K Tons (2017-2022)
  • Table 149. Brazil Decitabine Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 150. Brazil Decitabine Drug Sales, by End-user K Tons (2017-2022)
  • Table 151. Argentina Decitabine Drug Sales, by Type K Tons (2017-2022)
  • Table 152. Argentina Decitabine Drug Sales, by Application K Tons (2017-2022)
  • Table 153. Argentina Decitabine Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 154. Argentina Decitabine Drug Sales, by End-user K Tons (2017-2022)
  • Table 155. Rest of South America Decitabine Drug Sales, by Type K Tons (2017-2022)
  • Table 156. Rest of South America Decitabine Drug Sales, by Application K Tons (2017-2022)
  • Table 157. Rest of South America Decitabine Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 158. Rest of South America Decitabine Drug Sales, by End-user K Tons (2017-2022)
  • Table 159. Asia Pacific Decitabine Drug Sales, by Country K Tons (2017-2022)
  • Table 160. Asia Pacific Decitabine Drug Sales, by Type K Tons (2017-2022)
  • Table 161. Asia Pacific Decitabine Drug Sales, by Application K Tons (2017-2022)
  • Table 162. Asia Pacific Decitabine Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 163. Asia Pacific Decitabine Drug Sales, by End-user K Tons (2017-2022)
  • Table 164. China Decitabine Drug Sales, by Type K Tons (2017-2022)
  • Table 165. China Decitabine Drug Sales, by Application K Tons (2017-2022)
  • Table 166. China Decitabine Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 167. China Decitabine Drug Sales, by End-user K Tons (2017-2022)
  • Table 168. Japan Decitabine Drug Sales, by Type K Tons (2017-2022)
  • Table 169. Japan Decitabine Drug Sales, by Application K Tons (2017-2022)
  • Table 170. Japan Decitabine Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 171. Japan Decitabine Drug Sales, by End-user K Tons (2017-2022)
  • Table 172. India Decitabine Drug Sales, by Type K Tons (2017-2022)
  • Table 173. India Decitabine Drug Sales, by Application K Tons (2017-2022)
  • Table 174. India Decitabine Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 175. India Decitabine Drug Sales, by End-user K Tons (2017-2022)
  • Table 176. South Korea Decitabine Drug Sales, by Type K Tons (2017-2022)
  • Table 177. South Korea Decitabine Drug Sales, by Application K Tons (2017-2022)
  • Table 178. South Korea Decitabine Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 179. South Korea Decitabine Drug Sales, by End-user K Tons (2017-2022)
  • Table 180. Taiwan Decitabine Drug Sales, by Type K Tons (2017-2022)
  • Table 181. Taiwan Decitabine Drug Sales, by Application K Tons (2017-2022)
  • Table 182. Taiwan Decitabine Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 183. Taiwan Decitabine Drug Sales, by End-user K Tons (2017-2022)
  • Table 184. Australia Decitabine Drug Sales, by Type K Tons (2017-2022)
  • Table 185. Australia Decitabine Drug Sales, by Application K Tons (2017-2022)
  • Table 186. Australia Decitabine Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 187. Australia Decitabine Drug Sales, by End-user K Tons (2017-2022)
  • Table 188. Rest of Asia-Pacific Decitabine Drug Sales, by Type K Tons (2017-2022)
  • Table 189. Rest of Asia-Pacific Decitabine Drug Sales, by Application K Tons (2017-2022)
  • Table 190. Rest of Asia-Pacific Decitabine Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 191. Rest of Asia-Pacific Decitabine Drug Sales, by End-user K Tons (2017-2022)
  • Table 192. Europe Decitabine Drug Sales, by Country K Tons (2017-2022)
  • Table 193. Europe Decitabine Drug Sales, by Type K Tons (2017-2022)
  • Table 194. Europe Decitabine Drug Sales, by Application K Tons (2017-2022)
  • Table 195. Europe Decitabine Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 196. Europe Decitabine Drug Sales, by End-user K Tons (2017-2022)
  • Table 197. Germany Decitabine Drug Sales, by Type K Tons (2017-2022)
  • Table 198. Germany Decitabine Drug Sales, by Application K Tons (2017-2022)
  • Table 199. Germany Decitabine Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 200. Germany Decitabine Drug Sales, by End-user K Tons (2017-2022)
  • Table 201. France Decitabine Drug Sales, by Type K Tons (2017-2022)
  • Table 202. France Decitabine Drug Sales, by Application K Tons (2017-2022)
  • Table 203. France Decitabine Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 204. France Decitabine Drug Sales, by End-user K Tons (2017-2022)
  • Table 205. Italy Decitabine Drug Sales, by Type K Tons (2017-2022)
  • Table 206. Italy Decitabine Drug Sales, by Application K Tons (2017-2022)
  • Table 207. Italy Decitabine Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 208. Italy Decitabine Drug Sales, by End-user K Tons (2017-2022)
  • Table 209. United Kingdom Decitabine Drug Sales, by Type K Tons (2017-2022)
  • Table 210. United Kingdom Decitabine Drug Sales, by Application K Tons (2017-2022)
  • Table 211. United Kingdom Decitabine Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 212. United Kingdom Decitabine Drug Sales, by End-user K Tons (2017-2022)
  • Table 213. Netherlands Decitabine Drug Sales, by Type K Tons (2017-2022)
  • Table 214. Netherlands Decitabine Drug Sales, by Application K Tons (2017-2022)
  • Table 215. Netherlands Decitabine Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 216. Netherlands Decitabine Drug Sales, by End-user K Tons (2017-2022)
  • Table 217. Rest of Europe Decitabine Drug Sales, by Type K Tons (2017-2022)
  • Table 218. Rest of Europe Decitabine Drug Sales, by Application K Tons (2017-2022)
  • Table 219. Rest of Europe Decitabine Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 220. Rest of Europe Decitabine Drug Sales, by End-user K Tons (2017-2022)
  • Table 221. MEA Decitabine Drug Sales, by Country K Tons (2017-2022)
  • Table 222. MEA Decitabine Drug Sales, by Type K Tons (2017-2022)
  • Table 223. MEA Decitabine Drug Sales, by Application K Tons (2017-2022)
  • Table 224. MEA Decitabine Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 225. MEA Decitabine Drug Sales, by End-user K Tons (2017-2022)
  • Table 226. Middle East Decitabine Drug Sales, by Type K Tons (2017-2022)
  • Table 227. Middle East Decitabine Drug Sales, by Application K Tons (2017-2022)
  • Table 228. Middle East Decitabine Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 229. Middle East Decitabine Drug Sales, by End-user K Tons (2017-2022)
  • Table 230. Africa Decitabine Drug Sales, by Type K Tons (2017-2022)
  • Table 231. Africa Decitabine Drug Sales, by Application K Tons (2017-2022)
  • Table 232. Africa Decitabine Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 233. Africa Decitabine Drug Sales, by End-user K Tons (2017-2022)
  • Table 234. North America Decitabine Drug Sales, by Country K Tons (2017-2022)
  • Table 235. North America Decitabine Drug Sales, by Type K Tons (2017-2022)
  • Table 236. North America Decitabine Drug Sales, by Application K Tons (2017-2022)
  • Table 237. North America Decitabine Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 238. North America Decitabine Drug Sales, by End-user K Tons (2017-2022)
  • Table 239. United States Decitabine Drug Sales, by Type K Tons (2017-2022)
  • Table 240. United States Decitabine Drug Sales, by Application K Tons (2017-2022)
  • Table 241. United States Decitabine Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 242. United States Decitabine Drug Sales, by End-user K Tons (2017-2022)
  • Table 243. Canada Decitabine Drug Sales, by Type K Tons (2017-2022)
  • Table 244. Canada Decitabine Drug Sales, by Application K Tons (2017-2022)
  • Table 245. Canada Decitabine Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 246. Canada Decitabine Drug Sales, by End-user K Tons (2017-2022)
  • Table 247. Mexico Decitabine Drug Sales, by Type K Tons (2017-2022)
  • Table 248. Mexico Decitabine Drug Sales, by Application K Tons (2017-2022)
  • Table 249. Mexico Decitabine Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 250. Mexico Decitabine Drug Sales, by End-user K Tons (2017-2022)
  • Table 251. Decitabine Drug: by Type(USD/Units)
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Decitabine Drug: by Type(USD Million)
  • Table 263. Decitabine Drug Prescription , by Region USD Million (2023-2028)
  • Table 264. Decitabine Drug Over-the-Counter , by Region USD Million (2023-2028)
  • Table 265. Decitabine Drug: by Application(USD Million)
  • Table 266. Decitabine Drug Myelodysplastic syndrome , by Region USD Million (2023-2028)
  • Table 267. Decitabine Drug Acute Myeloid Leukemia , by Region USD Million (2023-2028)
  • Table 268. Decitabine Drug: by Distribution Channel(USD Million)
  • Table 269. Decitabine Drug Hospital Pharmacies , by Region USD Million (2023-2028)
  • Table 270. Decitabine Drug Drug Store , by Region USD Million (2023-2028)
  • Table 271. Decitabine Drug Retail Pharmacies , by Region USD Million (2023-2028)
  • Table 272. Decitabine Drug Online , by Region USD Million (2023-2028)
  • Table 273. Decitabine Drug Others , by Region USD Million (2023-2028)
  • Table 274. Decitabine Drug: by End-user(USD Million)
  • Table 275. Decitabine Drug Hospitals , by Region USD Million (2023-2028)
  • Table 276. Decitabine Drug Clinics , by Region USD Million (2023-2028)
  • Table 277. Decitabine Drug Others , by Region USD Million (2023-2028)
  • Table 278. South America Decitabine Drug, by Country USD Million (2023-2028)
  • Table 279. South America Decitabine Drug, by Type USD Million (2023-2028)
  • Table 280. South America Decitabine Drug, by Application USD Million (2023-2028)
  • Table 281. South America Decitabine Drug, by Distribution Channel USD Million (2023-2028)
  • Table 282. South America Decitabine Drug, by End-user USD Million (2023-2028)
  • Table 283. Brazil Decitabine Drug, by Type USD Million (2023-2028)
  • Table 284. Brazil Decitabine Drug, by Application USD Million (2023-2028)
  • Table 285. Brazil Decitabine Drug, by Distribution Channel USD Million (2023-2028)
  • Table 286. Brazil Decitabine Drug, by End-user USD Million (2023-2028)
  • Table 287. Argentina Decitabine Drug, by Type USD Million (2023-2028)
  • Table 288. Argentina Decitabine Drug, by Application USD Million (2023-2028)
  • Table 289. Argentina Decitabine Drug, by Distribution Channel USD Million (2023-2028)
  • Table 290. Argentina Decitabine Drug, by End-user USD Million (2023-2028)
  • Table 291. Rest of South America Decitabine Drug, by Type USD Million (2023-2028)
  • Table 292. Rest of South America Decitabine Drug, by Application USD Million (2023-2028)
  • Table 293. Rest of South America Decitabine Drug, by Distribution Channel USD Million (2023-2028)
  • Table 294. Rest of South America Decitabine Drug, by End-user USD Million (2023-2028)
  • Table 295. Asia Pacific Decitabine Drug, by Country USD Million (2023-2028)
  • Table 296. Asia Pacific Decitabine Drug, by Type USD Million (2023-2028)
  • Table 297. Asia Pacific Decitabine Drug, by Application USD Million (2023-2028)
  • Table 298. Asia Pacific Decitabine Drug, by Distribution Channel USD Million (2023-2028)
  • Table 299. Asia Pacific Decitabine Drug, by End-user USD Million (2023-2028)
  • Table 300. China Decitabine Drug, by Type USD Million (2023-2028)
  • Table 301. China Decitabine Drug, by Application USD Million (2023-2028)
  • Table 302. China Decitabine Drug, by Distribution Channel USD Million (2023-2028)
  • Table 303. China Decitabine Drug, by End-user USD Million (2023-2028)
  • Table 304. Japan Decitabine Drug, by Type USD Million (2023-2028)
  • Table 305. Japan Decitabine Drug, by Application USD Million (2023-2028)
  • Table 306. Japan Decitabine Drug, by Distribution Channel USD Million (2023-2028)
  • Table 307. Japan Decitabine Drug, by End-user USD Million (2023-2028)
  • Table 308. India Decitabine Drug, by Type USD Million (2023-2028)
  • Table 309. India Decitabine Drug, by Application USD Million (2023-2028)
  • Table 310. India Decitabine Drug, by Distribution Channel USD Million (2023-2028)
  • Table 311. India Decitabine Drug, by End-user USD Million (2023-2028)
  • Table 312. South Korea Decitabine Drug, by Type USD Million (2023-2028)
  • Table 313. South Korea Decitabine Drug, by Application USD Million (2023-2028)
  • Table 314. South Korea Decitabine Drug, by Distribution Channel USD Million (2023-2028)
  • Table 315. South Korea Decitabine Drug, by End-user USD Million (2023-2028)
  • Table 316. Taiwan Decitabine Drug, by Type USD Million (2023-2028)
  • Table 317. Taiwan Decitabine Drug, by Application USD Million (2023-2028)
  • Table 318. Taiwan Decitabine Drug, by Distribution Channel USD Million (2023-2028)
  • Table 319. Taiwan Decitabine Drug, by End-user USD Million (2023-2028)
  • Table 320. Australia Decitabine Drug, by Type USD Million (2023-2028)
  • Table 321. Australia Decitabine Drug, by Application USD Million (2023-2028)
  • Table 322. Australia Decitabine Drug, by Distribution Channel USD Million (2023-2028)
  • Table 323. Australia Decitabine Drug, by End-user USD Million (2023-2028)
  • Table 324. Rest of Asia-Pacific Decitabine Drug, by Type USD Million (2023-2028)
  • Table 325. Rest of Asia-Pacific Decitabine Drug, by Application USD Million (2023-2028)
  • Table 326. Rest of Asia-Pacific Decitabine Drug, by Distribution Channel USD Million (2023-2028)
  • Table 327. Rest of Asia-Pacific Decitabine Drug, by End-user USD Million (2023-2028)
  • Table 328. Europe Decitabine Drug, by Country USD Million (2023-2028)
  • Table 329. Europe Decitabine Drug, by Type USD Million (2023-2028)
  • Table 330. Europe Decitabine Drug, by Application USD Million (2023-2028)
  • Table 331. Europe Decitabine Drug, by Distribution Channel USD Million (2023-2028)
  • Table 332. Europe Decitabine Drug, by End-user USD Million (2023-2028)
  • Table 333. Germany Decitabine Drug, by Type USD Million (2023-2028)
  • Table 334. Germany Decitabine Drug, by Application USD Million (2023-2028)
  • Table 335. Germany Decitabine Drug, by Distribution Channel USD Million (2023-2028)
  • Table 336. Germany Decitabine Drug, by End-user USD Million (2023-2028)
  • Table 337. France Decitabine Drug, by Type USD Million (2023-2028)
  • Table 338. France Decitabine Drug, by Application USD Million (2023-2028)
  • Table 339. France Decitabine Drug, by Distribution Channel USD Million (2023-2028)
  • Table 340. France Decitabine Drug, by End-user USD Million (2023-2028)
  • Table 341. Italy Decitabine Drug, by Type USD Million (2023-2028)
  • Table 342. Italy Decitabine Drug, by Application USD Million (2023-2028)
  • Table 343. Italy Decitabine Drug, by Distribution Channel USD Million (2023-2028)
  • Table 344. Italy Decitabine Drug, by End-user USD Million (2023-2028)
  • Table 345. United Kingdom Decitabine Drug, by Type USD Million (2023-2028)
  • Table 346. United Kingdom Decitabine Drug, by Application USD Million (2023-2028)
  • Table 347. United Kingdom Decitabine Drug, by Distribution Channel USD Million (2023-2028)
  • Table 348. United Kingdom Decitabine Drug, by End-user USD Million (2023-2028)
  • Table 349. Netherlands Decitabine Drug, by Type USD Million (2023-2028)
  • Table 350. Netherlands Decitabine Drug, by Application USD Million (2023-2028)
  • Table 351. Netherlands Decitabine Drug, by Distribution Channel USD Million (2023-2028)
  • Table 352. Netherlands Decitabine Drug, by End-user USD Million (2023-2028)
  • Table 353. Rest of Europe Decitabine Drug, by Type USD Million (2023-2028)
  • Table 354. Rest of Europe Decitabine Drug, by Application USD Million (2023-2028)
  • Table 355. Rest of Europe Decitabine Drug, by Distribution Channel USD Million (2023-2028)
  • Table 356. Rest of Europe Decitabine Drug, by End-user USD Million (2023-2028)
  • Table 357. MEA Decitabine Drug, by Country USD Million (2023-2028)
  • Table 358. MEA Decitabine Drug, by Type USD Million (2023-2028)
  • Table 359. MEA Decitabine Drug, by Application USD Million (2023-2028)
  • Table 360. MEA Decitabine Drug, by Distribution Channel USD Million (2023-2028)
  • Table 361. MEA Decitabine Drug, by End-user USD Million (2023-2028)
  • Table 362. Middle East Decitabine Drug, by Type USD Million (2023-2028)
  • Table 363. Middle East Decitabine Drug, by Application USD Million (2023-2028)
  • Table 364. Middle East Decitabine Drug, by Distribution Channel USD Million (2023-2028)
  • Table 365. Middle East Decitabine Drug, by End-user USD Million (2023-2028)
  • Table 366. Africa Decitabine Drug, by Type USD Million (2023-2028)
  • Table 367. Africa Decitabine Drug, by Application USD Million (2023-2028)
  • Table 368. Africa Decitabine Drug, by Distribution Channel USD Million (2023-2028)
  • Table 369. Africa Decitabine Drug, by End-user USD Million (2023-2028)
  • Table 370. North America Decitabine Drug, by Country USD Million (2023-2028)
  • Table 371. North America Decitabine Drug, by Type USD Million (2023-2028)
  • Table 372. North America Decitabine Drug, by Application USD Million (2023-2028)
  • Table 373. North America Decitabine Drug, by Distribution Channel USD Million (2023-2028)
  • Table 374. North America Decitabine Drug, by End-user USD Million (2023-2028)
  • Table 375. United States Decitabine Drug, by Type USD Million (2023-2028)
  • Table 376. United States Decitabine Drug, by Application USD Million (2023-2028)
  • Table 377. United States Decitabine Drug, by Distribution Channel USD Million (2023-2028)
  • Table 378. United States Decitabine Drug, by End-user USD Million (2023-2028)
  • Table 379. Canada Decitabine Drug, by Type USD Million (2023-2028)
  • Table 380. Canada Decitabine Drug, by Application USD Million (2023-2028)
  • Table 381. Canada Decitabine Drug, by Distribution Channel USD Million (2023-2028)
  • Table 382. Canada Decitabine Drug, by End-user USD Million (2023-2028)
  • Table 383. Mexico Decitabine Drug, by Type USD Million (2023-2028)
  • Table 384. Mexico Decitabine Drug, by Application USD Million (2023-2028)
  • Table 385. Mexico Decitabine Drug, by Distribution Channel USD Million (2023-2028)
  • Table 386. Mexico Decitabine Drug, by End-user USD Million (2023-2028)
  • Table 387. Decitabine Drug Sales: by Type(K Tons)
  • Table 388. Decitabine Drug Sales Prescription , by Region K Tons (2023-2028)
  • Table 389. Decitabine Drug Sales Over-the-Counter , by Region K Tons (2023-2028)
  • Table 390. Decitabine Drug Sales: by Application(K Tons)
  • Table 391. Decitabine Drug Sales Myelodysplastic syndrome , by Region K Tons (2023-2028)
  • Table 392. Decitabine Drug Sales Acute Myeloid Leukemia , by Region K Tons (2023-2028)
  • Table 393. Decitabine Drug Sales: by Distribution Channel(K Tons)
  • Table 394. Decitabine Drug Sales Hospital Pharmacies , by Region K Tons (2023-2028)
  • Table 395. Decitabine Drug Sales Drug Store , by Region K Tons (2023-2028)
  • Table 396. Decitabine Drug Sales Retail Pharmacies , by Region K Tons (2023-2028)
  • Table 397. Decitabine Drug Sales Online , by Region K Tons (2023-2028)
  • Table 398. Decitabine Drug Sales Others , by Region K Tons (2023-2028)
  • Table 399. Decitabine Drug Sales: by End-user(K Tons)
  • Table 400. Decitabine Drug Sales Hospitals , by Region K Tons (2023-2028)
  • Table 401. Decitabine Drug Sales Clinics , by Region K Tons (2023-2028)
  • Table 402. Decitabine Drug Sales Others , by Region K Tons (2023-2028)
  • Table 403. South America Decitabine Drug Sales, by Country K Tons (2023-2028)
  • Table 404. South America Decitabine Drug Sales, by Type K Tons (2023-2028)
  • Table 405. South America Decitabine Drug Sales, by Application K Tons (2023-2028)
  • Table 406. South America Decitabine Drug Sales, by Distribution Channel K Tons (2023-2028)
  • Table 407. South America Decitabine Drug Sales, by End-user K Tons (2023-2028)
  • Table 408. Brazil Decitabine Drug Sales, by Type K Tons (2023-2028)
  • Table 409. Brazil Decitabine Drug Sales, by Application K Tons (2023-2028)
  • Table 410. Brazil Decitabine Drug Sales, by Distribution Channel K Tons (2023-2028)
  • Table 411. Brazil Decitabine Drug Sales, by End-user K Tons (2023-2028)
  • Table 412. Argentina Decitabine Drug Sales, by Type K Tons (2023-2028)
  • Table 413. Argentina Decitabine Drug Sales, by Application K Tons (2023-2028)
  • Table 414. Argentina Decitabine Drug Sales, by Distribution Channel K Tons (2023-2028)
  • Table 415. Argentina Decitabine Drug Sales, by End-user K Tons (2023-2028)
  • Table 416. Rest of South America Decitabine Drug Sales, by Type K Tons (2023-2028)
  • Table 417. Rest of South America Decitabine Drug Sales, by Application K Tons (2023-2028)
  • Table 418. Rest of South America Decitabine Drug Sales, by Distribution Channel K Tons (2023-2028)
  • Table 419. Rest of South America Decitabine Drug Sales, by End-user K Tons (2023-2028)
  • Table 420. Asia Pacific Decitabine Drug Sales, by Country K Tons (2023-2028)
  • Table 421. Asia Pacific Decitabine Drug Sales, by Type K Tons (2023-2028)
  • Table 422. Asia Pacific Decitabine Drug Sales, by Application K Tons (2023-2028)
  • Table 423. Asia Pacific Decitabine Drug Sales, by Distribution Channel K Tons (2023-2028)
  • Table 424. Asia Pacific Decitabine Drug Sales, by End-user K Tons (2023-2028)
  • Table 425. China Decitabine Drug Sales, by Type K Tons (2023-2028)
  • Table 426. China Decitabine Drug Sales, by Application K Tons (2023-2028)
  • Table 427. China Decitabine Drug Sales, by Distribution Channel K Tons (2023-2028)
  • Table 428. China Decitabine Drug Sales, by End-user K Tons (2023-2028)
  • Table 429. Japan Decitabine Drug Sales, by Type K Tons (2023-2028)
  • Table 430. Japan Decitabine Drug Sales, by Application K Tons (2023-2028)
  • Table 431. Japan Decitabine Drug Sales, by Distribution Channel K Tons (2023-2028)
  • Table 432. Japan Decitabine Drug Sales, by End-user K Tons (2023-2028)
  • Table 433. India Decitabine Drug Sales, by Type K Tons (2023-2028)
  • Table 434. India Decitabine Drug Sales, by Application K Tons (2023-2028)
  • Table 435. India Decitabine Drug Sales, by Distribution Channel K Tons (2023-2028)
  • Table 436. India Decitabine Drug Sales, by End-user K Tons (2023-2028)
  • Table 437. South Korea Decitabine Drug Sales, by Type K Tons (2023-2028)
  • Table 438. South Korea Decitabine Drug Sales, by Application K Tons (2023-2028)
  • Table 439. South Korea Decitabine Drug Sales, by Distribution Channel K Tons (2023-2028)
  • Table 440. South Korea Decitabine Drug Sales, by End-user K Tons (2023-2028)
  • Table 441. Taiwan Decitabine Drug Sales, by Type K Tons (2023-2028)
  • Table 442. Taiwan Decitabine Drug Sales, by Application K Tons (2023-2028)
  • Table 443. Taiwan Decitabine Drug Sales, by Distribution Channel K Tons (2023-2028)
  • Table 444. Taiwan Decitabine Drug Sales, by End-user K Tons (2023-2028)
  • Table 445. Australia Decitabine Drug Sales, by Type K Tons (2023-2028)
  • Table 446. Australia Decitabine Drug Sales, by Application K Tons (2023-2028)
  • Table 447. Australia Decitabine Drug Sales, by Distribution Channel K Tons (2023-2028)
  • Table 448. Australia Decitabine Drug Sales, by End-user K Tons (2023-2028)
  • Table 449. Rest of Asia-Pacific Decitabine Drug Sales, by Type K Tons (2023-2028)
  • Table 450. Rest of Asia-Pacific Decitabine Drug Sales, by Application K Tons (2023-2028)
  • Table 451. Rest of Asia-Pacific Decitabine Drug Sales, by Distribution Channel K Tons (2023-2028)
  • Table 452. Rest of Asia-Pacific Decitabine Drug Sales, by End-user K Tons (2023-2028)
  • Table 453. Europe Decitabine Drug Sales, by Country K Tons (2023-2028)
  • Table 454. Europe Decitabine Drug Sales, by Type K Tons (2023-2028)
  • Table 455. Europe Decitabine Drug Sales, by Application K Tons (2023-2028)
  • Table 456. Europe Decitabine Drug Sales, by Distribution Channel K Tons (2023-2028)
  • Table 457. Europe Decitabine Drug Sales, by End-user K Tons (2023-2028)
  • Table 458. Germany Decitabine Drug Sales, by Type K Tons (2023-2028)
  • Table 459. Germany Decitabine Drug Sales, by Application K Tons (2023-2028)
  • Table 460. Germany Decitabine Drug Sales, by Distribution Channel K Tons (2023-2028)
  • Table 461. Germany Decitabine Drug Sales, by End-user K Tons (2023-2028)
  • Table 462. France Decitabine Drug Sales, by Type K Tons (2023-2028)
  • Table 463. France Decitabine Drug Sales, by Application K Tons (2023-2028)
  • Table 464. France Decitabine Drug Sales, by Distribution Channel K Tons (2023-2028)
  • Table 465. France Decitabine Drug Sales, by End-user K Tons (2023-2028)
  • Table 466. Italy Decitabine Drug Sales, by Type K Tons (2023-2028)
  • Table 467. Italy Decitabine Drug Sales, by Application K Tons (2023-2028)
  • Table 468. Italy Decitabine Drug Sales, by Distribution Channel K Tons (2023-2028)
  • Table 469. Italy Decitabine Drug Sales, by End-user K Tons (2023-2028)
  • Table 470. United Kingdom Decitabine Drug Sales, by Type K Tons (2023-2028)
  • Table 471. United Kingdom Decitabine Drug Sales, by Application K Tons (2023-2028)
  • Table 472. United Kingdom Decitabine Drug Sales, by Distribution Channel K Tons (2023-2028)
  • Table 473. United Kingdom Decitabine Drug Sales, by End-user K Tons (2023-2028)
  • Table 474. Netherlands Decitabine Drug Sales, by Type K Tons (2023-2028)
  • Table 475. Netherlands Decitabine Drug Sales, by Application K Tons (2023-2028)
  • Table 476. Netherlands Decitabine Drug Sales, by Distribution Channel K Tons (2023-2028)
  • Table 477. Netherlands Decitabine Drug Sales, by End-user K Tons (2023-2028)
  • Table 478. Rest of Europe Decitabine Drug Sales, by Type K Tons (2023-2028)
  • Table 479. Rest of Europe Decitabine Drug Sales, by Application K Tons (2023-2028)
  • Table 480. Rest of Europe Decitabine Drug Sales, by Distribution Channel K Tons (2023-2028)
  • Table 481. Rest of Europe Decitabine Drug Sales, by End-user K Tons (2023-2028)
  • Table 482. MEA Decitabine Drug Sales, by Country K Tons (2023-2028)
  • Table 483. MEA Decitabine Drug Sales, by Type K Tons (2023-2028)
  • Table 484. MEA Decitabine Drug Sales, by Application K Tons (2023-2028)
  • Table 485. MEA Decitabine Drug Sales, by Distribution Channel K Tons (2023-2028)
  • Table 486. MEA Decitabine Drug Sales, by End-user K Tons (2023-2028)
  • Table 487. Middle East Decitabine Drug Sales, by Type K Tons (2023-2028)
  • Table 488. Middle East Decitabine Drug Sales, by Application K Tons (2023-2028)
  • Table 489. Middle East Decitabine Drug Sales, by Distribution Channel K Tons (2023-2028)
  • Table 490. Middle East Decitabine Drug Sales, by End-user K Tons (2023-2028)
  • Table 491. Africa Decitabine Drug Sales, by Type K Tons (2023-2028)
  • Table 492. Africa Decitabine Drug Sales, by Application K Tons (2023-2028)
  • Table 493. Africa Decitabine Drug Sales, by Distribution Channel K Tons (2023-2028)
  • Table 494. Africa Decitabine Drug Sales, by End-user K Tons (2023-2028)
  • Table 495. North America Decitabine Drug Sales, by Country K Tons (2023-2028)
  • Table 496. North America Decitabine Drug Sales, by Type K Tons (2023-2028)
  • Table 497. North America Decitabine Drug Sales, by Application K Tons (2023-2028)
  • Table 498. North America Decitabine Drug Sales, by Distribution Channel K Tons (2023-2028)
  • Table 499. North America Decitabine Drug Sales, by End-user K Tons (2023-2028)
  • Table 500. United States Decitabine Drug Sales, by Type K Tons (2023-2028)
  • Table 501. United States Decitabine Drug Sales, by Application K Tons (2023-2028)
  • Table 502. United States Decitabine Drug Sales, by Distribution Channel K Tons (2023-2028)
  • Table 503. United States Decitabine Drug Sales, by End-user K Tons (2023-2028)
  • Table 504. Canada Decitabine Drug Sales, by Type K Tons (2023-2028)
  • Table 505. Canada Decitabine Drug Sales, by Application K Tons (2023-2028)
  • Table 506. Canada Decitabine Drug Sales, by Distribution Channel K Tons (2023-2028)
  • Table 507. Canada Decitabine Drug Sales, by End-user K Tons (2023-2028)
  • Table 508. Mexico Decitabine Drug Sales, by Type K Tons (2023-2028)
  • Table 509. Mexico Decitabine Drug Sales, by Application K Tons (2023-2028)
  • Table 510. Mexico Decitabine Drug Sales, by Distribution Channel K Tons (2023-2028)
  • Table 511. Mexico Decitabine Drug Sales, by End-user K Tons (2023-2028)
  • Table 512. Decitabine Drug: by Type(USD/Units)
  • Table 513. Research Programs/Design for This Report
  • Table 514. Key Data Information from Secondary Sources
  • Table 515. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Decitabine Drug: by Type USD Million (2017-2022)
  • Figure 5. Global Decitabine Drug: by Application USD Million (2017-2022)
  • Figure 6. Global Decitabine Drug: by Distribution Channel USD Million (2017-2022)
  • Figure 7. Global Decitabine Drug: by End-user USD Million (2017-2022)
  • Figure 8. South America Decitabine Drug Share (%), by Country
  • Figure 9. Asia Pacific Decitabine Drug Share (%), by Country
  • Figure 10. Europe Decitabine Drug Share (%), by Country
  • Figure 11. MEA Decitabine Drug Share (%), by Country
  • Figure 12. North America Decitabine Drug Share (%), by Country
  • Figure 13. Global Decitabine Drug: by Type K Tons (2017-2022)
  • Figure 14. Global Decitabine Drug: by Application K Tons (2017-2022)
  • Figure 15. Global Decitabine Drug: by Distribution Channel K Tons (2017-2022)
  • Figure 16. Global Decitabine Drug: by End-user K Tons (2017-2022)
  • Figure 17. South America Decitabine Drug Share (%), by Country
  • Figure 18. Asia Pacific Decitabine Drug Share (%), by Country
  • Figure 19. Europe Decitabine Drug Share (%), by Country
  • Figure 20. MEA Decitabine Drug Share (%), by Country
  • Figure 21. North America Decitabine Drug Share (%), by Country
  • Figure 22. Global Decitabine Drug: by Type USD/Units (2017-2022)
  • Figure 23. Global Decitabine Drug share by Players 2022 (%)
  • Figure 24. Global Decitabine Drug share by Players (Top 3) 2022(%)
  • Figure 25. Global Decitabine Drug share by Players (Top 5) 2022(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. ScinoPharm (Taiwan) Revenue, Net Income and Gross profit
  • Figure 28. ScinoPharm (Taiwan) Revenue: by Geography 2022
  • Figure 29. Otsuka Pharmaceutical Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 30. Otsuka Pharmaceutical Co., Ltd. (Japan) Revenue: by Geography 2022
  • Figure 31. Sandoz (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Sandoz (Germany) Revenue: by Geography 2022
  • Figure 33. Dr. Reddy's Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 34. Dr. Reddy's Laboratories (India) Revenue: by Geography 2022
  • Figure 35. Midas Pharma GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Midas Pharma GmbH (Germany) Revenue: by Geography 2022
  • Figure 37. LGM Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 38. LGM Pharma (United States) Revenue: by Geography 2022
  • Figure 39. Astex Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 40. Astex Therapeutics (United States) Revenue: by Geography 2022
  • Figure 41. Accord Healthcare Ltd. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 42. Accord Healthcare Ltd. (United Kingdom) Revenue: by Geography 2022
  • Figure 43. Sun Pharmaceutical Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 44. Sun Pharmaceutical Industries Ltd. (India) Revenue: by Geography 2022
  • Figure 45. Cipla (India) Revenue, Net Income and Gross profit
  • Figure 46. Cipla (India) Revenue: by Geography 2022
  • Figure 47. Global Decitabine Drug: by Type USD Million (2023-2028)
  • Figure 48. Global Decitabine Drug: by Application USD Million (2023-2028)
  • Figure 49. Global Decitabine Drug: by Distribution Channel USD Million (2023-2028)
  • Figure 50. Global Decitabine Drug: by End-user USD Million (2023-2028)
  • Figure 51. South America Decitabine Drug Share (%), by Country
  • Figure 52. Asia Pacific Decitabine Drug Share (%), by Country
  • Figure 53. Europe Decitabine Drug Share (%), by Country
  • Figure 54. MEA Decitabine Drug Share (%), by Country
  • Figure 55. North America Decitabine Drug Share (%), by Country
  • Figure 56. Global Decitabine Drug: by Type K Tons (2023-2028)
  • Figure 57. Global Decitabine Drug: by Application K Tons (2023-2028)
  • Figure 58. Global Decitabine Drug: by Distribution Channel K Tons (2023-2028)
  • Figure 59. Global Decitabine Drug: by End-user K Tons (2023-2028)
  • Figure 60. South America Decitabine Drug Share (%), by Country
  • Figure 61. Asia Pacific Decitabine Drug Share (%), by Country
  • Figure 62. Europe Decitabine Drug Share (%), by Country
  • Figure 63. MEA Decitabine Drug Share (%), by Country
  • Figure 64. North America Decitabine Drug Share (%), by Country
  • Figure 65. Global Decitabine Drug: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • ScinoPharm (Taiwan)
  • Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Sandoz (Germany)
  • Dr. Reddy's Laboratories (India)
  • Midas Pharma GmbH (Germany)
  • LGM Pharma (United States)
  • Astex Therapeutics (United States)
  • Accord Healthcare Ltd. (United Kingdom)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Cipla (India)
Additional players considered in the study are as follows:
Beijing Lunarsun Pharmaceutical Co., Ltd. (China) , Lupin (India) , Taj Pharmaceuticals Limited (India) , Innopharma, Inc. (United States)
Select User Access Type

Key Highlights of Report


May 2023 247 Pages 76 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Decitabine Drug Market Quantitative research analysis
Global Decitabine Drug Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increased Prevalence of Myelodysplastic Syndrome among People " is seen as one of major growth factors of Decitabine Drug Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
The Decitabine Drug market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Decitabine Drug Market Report?

Have a Query? Click Here

Other Related Reports

Gastric Carcinomas Drugs Comprehensive Study by Drugs (Ramucirumab, Docetaxel, Doxorubicin Hydrochloride, Fluorouracil, Others), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, E-Comme...
$ 3750
Pharyngitis Tablets Comprehensive Study by Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies), Source (Viral, Bacterial), Symptoms (Sore Throat, Fever, Runny Nose, Cough, Headache...
$ 3500
Gemtuzumab Ozogamicin Drugs Comprehensive Study by Type (5mg/Vial, 4.5mg/Vial), Application (Hospital, Pharmacy) Players and Region - Global Market Outlook to 2030
$ 3500
Terbinafine Tablet Comprehensive Study by Application (Athlete's Foot, Jock Itch, Ringworm, Others), Route of Administration (Oral Medication, External Medicine), Distribution Channel (Hospital Pharm...
$ 3450
Psychotherapeutics Drugs Comprehensive Study by Application (Schizophrenia, Dementia, Bipolar, Unipolar Depression), Drugs Class (Antipsychotic Drugs, (Thioxanthenes, Atypical Antipsychotics, Phenoth...
$ 3750
Timolol Comprehensive Study by Type (Tablet (5mg, 10mg and 20mg), Eye Drops (3ml Drops, 5ml Drops and Others)), Application (Open-Angle Glaucoma, Ocular Hypertension), Distribution Channel (Hospital ...
$ 3450